LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN.UK

13,514

-3.07%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN.UK

13,514

-3.07%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN.UK

13,514

-3.07%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN.UK

13,514

-3.07%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN.UK

13,514

-3.07%↓

Inicio・Lista de Acciones・AstraZeneca PLC

AstraZeneca PLC

Cerrado

SectorSanidad

181.62 -1.79

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

180.4

Máximo

184.95

Métricas clave
By Trading Economics
Ingresos	1.6B 3.9B
Ventas	-215M 15B
P/B Media del Sector	27.389 51.415
BPA	1.29
Rentabilidad por dividendo	1.75
Margen de beneficios	25.602
Empleados	96,100
EBITDA	1.1B 5.7B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+16.18% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	1.75% 2.34%
Próximas Ganancias	27 jul 2026
Próxima Fecha de Ex Dividendo	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-8.7B 282B
Apertura anterior	183.41
Cierre anterior	181.62

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

53 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

N/A / 69.55 Soporte y Resistencia

AstraZeneca PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2026, 16:28 UTC

Ganancias

Correction to AstraZeneca Update

29 abr 2026, 15:11 UTC

Ganancias

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

29 abr 2026, 06:31 UTC

Ganancias

AstraZeneca Gets Revenue Boost From Cancer Drugs

27 mar 2026, 10:04 UTC

Noticias de Eventos Importantes

Oil Climbs Higher, Stock Recovery Fades as Doubts Cloud Cease-Fire Hopes

13 may 2026, 12:29 UTC

Charlas de Mercado

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

13 may 2026, 11:54 UTC

Charlas de Mercado

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

1 may 2026, 09:31 UTC

Charlas de Mercado

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

29 abr 2026, 10:29 UTC

Charlas de Mercado

Ganancias

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

29 abr 2026, 10:06 UTC

Charlas de Mercado

Ganancias

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 abr 2026, 09:53 UTC

Charlas de Mercado

Ganancias

AstraZeneca Seems in Fine Health -- Market Talk

29 abr 2026, 06:05 UTC

Ganancias

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

29 abr 2026, 06:04 UTC

Ganancias

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

29 abr 2026, 06:04 UTC

Ganancias

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

29 abr 2026, 06:03 UTC

Ganancias

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

29 abr 2026, 06:03 UTC

Ganancias

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

29 abr 2026, 06:02 UTC

Ganancias

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

29 abr 2026, 06:01 UTC

Ganancias

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

29 abr 2026, 06:01 UTC

Ganancias

AstraZeneca Backs 2026 View

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Adj EPS $2.58

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Rev $15.29B

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Pretax Pft $3.91B

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Oper Pft $4.25B

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Net Pft $3.08B

29 abr 2026, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q EPS $1.97

27 abr 2026, 10:48 UTC

Charlas de Mercado

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

10 abr 2026, 11:57 UTC

Charlas de Mercado

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

10 abr 2026, 10:26 UTC

Charlas de Mercado

Ganancias

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2 abr 2026, 09:16 UTC

Charlas de Mercado

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

27 mar 2026, 10:40 UTC

Charlas de Mercado

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

27 mar 2026, 10:17 UTC

Charlas de Mercado

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Comparación entre iguales

Cambio de precio

AstraZeneca PLC previsión

Precio Objetivo

By TipRanks

16.18% repunte

Estimación a 12 Meses

Media 214.879 USD 16.18%

Máximo 248.602 USD

Mínimo 151.032 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para AstraZeneca PLC Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 69.55Soporte y Resistencia

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

53 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.